PolyPid Ltd.

NasdaqCM PYPD

PolyPid Ltd. Operating Cash Flow for the year ending December 31, 2023: USD -17.24 M

PolyPid Ltd. Operating Cash Flow is USD -17.24 M for the year ending December 31, 2023, a 49.77% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

PolyPid Ltd. Operating Cash Flow for the year ending December 31, 2022 was USD -34.32 M, a -5.96% change year over year.
PolyPid Ltd. Operating Cash Flow for the year ending December 31, 2021 was USD -32.39 M, a -49.96% change year over year.
PolyPid Ltd. Operating Cash Flow for the year ending December 31, 2020 was USD -21.60 M, a -24.42% change year over year.
PolyPid Ltd. Operating Cash Flow for the year ending December 31, 2019 was USD -17.36 M, a -4.08% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

NasdaqCM: PYPD

PolyPid Ltd.

CEO	Ms. Dikla Czaczkes Akselbrad
IPO Date	June 26, 2020
Location	Israel
Headquarters	18 Hasivim Street
Employees	59
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Medical Instruments Pharmaceuticals Plastics Vaccines

Description

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in Phase III clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Key trends

Past 5 years